Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0

NCT01621217 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT01621217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
Lead sponsor
Lund University Hospital
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
January 31, 2020
Enrollment
21 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cancer in the anal region